阿斯利康
AZN92.900USD
+0.450+0.49%
收盘 12/26, 16:00（美东）报价延迟15分钟
288.12B总市值
30.64市盈率 TTM
关于 阿斯利康 公司
阿斯特捷利康是一家科研驱动的全球生物制药企业，致力于将科学突破快速转化为患者可及的治疗选项，专注肿瘤、罕见疾病以及心血管、肾脏代谢、呼吸与免疫等领域的处方创新，并拓展疫苗与免疫疗法。公司核心肿瘤药物组合涵盖 Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Zoladex、Faslodex 等；罕见病线持续拥有 Soliris、Ultomiris、Strensiq、Kanuma；生物制药线提供 Farxiga、Crestor、Breztri 等多款产品。当前研发管线中，候选疫苗 IVX-A12 用于应对呼吸道合胞病毒与人类偏肺病毒，肿瘤候选药 FPI-2265 靶向转移性去势抵抗性前列腺癌，并正开展 II 期临床研究。公司同时积极投入 T 细胞受体疗法与治疗肽 Eneboparatide 的开发工作。
阿斯利康简介
公司代码AZN
公司名称AstraZeneca PLC
上市日期Sep 21, 2007
CEODunoyer (Marc)
员工数量94300
证券类型Depository Receipt
年结日Sep 21
公司地址1 Francis Crick Avenue
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United Kingdom
邮编CB2 0AA
电话442073045000
网址https://www.astrazeneca.com/
公司代码AZN
上市日期Sep 21, 2007
CEODunoyer (Marc)
阿斯利康公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Ms. Diana Layfield
Ms. Diana Layfield
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Rene Haas
Mr. Rene Haas
Non-Executive Director
Non-Executive Director
--
--
Mr. Michel Demare
Mr. Michel Demare
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Aradhana Sarin, M.D.
Ms. Aradhana Sarin, M.D.
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Farxiga
2.15B
15.59%
Tagrisso
1.81B
13.12%
Imfinzi
1.46B
10.55%
Ultomiris
1.18B
8.53%
Calquenc
872.00M
6.32%
其他
6.33B
45.89%
地区USD
名称
营收
占比
United States
6.32B
45.84%
Europe
3.07B
22.23%
EX-China
2.04B
14.82%
China
1.71B
12.40%
Established ROW
1.31B
9.53%
业务
地区
业务USD
名称
营收
占比
Farxiga
2.15B
15.59%
Tagrisso
1.81B
13.12%
Imfinzi
1.46B
10.55%
Ultomiris
1.18B
8.53%
Calquenc
872.00M
6.32%
其他
6.33B
45.89%
股东统计
更新时间: 11月25日 周二
更新时间: 11月25日 周二
持股股东
股东类型
持股股东
持股股东
占比
PRIMECAP Management Company
1.29%
Wellington Management Company, LLP
1.04%
T. Rowe Price International Ltd
1.00%
Capital International Investors
0.81%
Managed Account Advisors LLC
0.72%
其他
95.15%
持股股东
持股股东
占比
PRIMECAP Management Company
1.29%
Wellington Management Company, LLP
1.04%
T. Rowe Price International Ltd
1.00%
Capital International Investors
0.81%
Managed Account Advisors LLC
0.72%
其他
95.15%
股东类型
持股股东
占比
Investment Advisor
8.78%
Investment Advisor/Hedge Fund
5.84%
Research Firm
1.11%
Hedge Fund
0.69%
Bank and Trust
0.19%
Pension Fund
0.06%
Venture Capital
0.03%
Family Office
0.02%
Family Office
0.02%
其他
83.26%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
2038
518.15M
17.29%
+1.97M
2025Q3
2089
516.24M
17.34%
-2.62M
2025Q2
2062
519.46M
17.59%
-9.37M
2025Q1
2054
529.82M
17.91%
-25.96M
2024Q4
2001
537.38M
17.35%
+13.04M
2024Q3
1925
524.26M
17.32%
+244.85K
2024Q2
1912
524.03M
17.41%
+1.94M
2024Q1
1863
521.64M
17.31%
-15.18M
2023Q4
1837
514.30M
17.42%
-5.99M
2023Q3
1809
522.19M
17.30%
+4.27M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
PRIMECAP Management Company
41.20M
1.33%
+538.61K
+1.32%
Jun 30, 2025
Wellington Management Company, LLP
34.34M
1.11%
-1.29M
-3.63%
Jun 30, 2025
T. Rowe Price International Ltd
30.71M
0.99%
+3.43M
+12.56%
Jun 30, 2025
Capital International Investors
31.40M
1.01%
+119.42K
+0.38%
Jun 30, 2025
Managed Account Advisors LLC
21.15M
0.68%
-1.37M
-6.07%
Jun 30, 2025
Fisher Investments
20.70M
0.67%
+530.52K
+2.63%
Jun 30, 2025
Fidelity Management & Research Company LLC
18.04M
0.58%
-944.35K
-4.97%
Jun 30, 2025
T. Rowe Price Associates, Inc.
21.24M
0.68%
-8.57M
-28.75%
Jun 30, 2025
Sanders Capital, LLC
14.53M
0.47%
-542.12K
-3.60%
Jun 30, 2025
Putnam Investment Management, L.L.C.
12.48M
0.4%
+184.41K
+1.50%
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月1日 周三
更新时间: 10月1日 周三
机构名称
占比
Amplify Weight Loss Drug & Treatment ETF
5.58%
VanEck Pharmaceutical ETF
4.97%
Invesco Nasdaq Biotechnology ETF
4.81%
ProShares Ultra Nasdaq Biotechnology
4.81%
Parnassus Value Select ETF
4.66%
Invesco QQQ Low Volatility ETF
4.19%
Roundhill GLP-1 & Weight Loss ETF
3.36%
Abacus FCF International Leaders ETF
3.28%
Global X Aging Population ETF
3.2%
Franklin Genomic Advancements ETF
3.05%
查看更多
Amplify Weight Loss Drug & Treatment ETF
占比5.58%
VanEck Pharmaceutical ETF
占比4.97%
Invesco Nasdaq Biotechnology ETF
占比4.81%
ProShares Ultra Nasdaq Biotechnology
占比4.81%
Parnassus Value Select ETF
占比4.66%
Invesco QQQ Low Volatility ETF
占比4.19%
Roundhill GLP-1 & Weight Loss ETF
占比3.36%
Abacus FCF International Leaders ETF
占比3.28%
Global X Aging Population ETF
占比3.2%
Franklin Genomic Advancements ETF
占比3.05%
分红派息
近5年累计派现
20.90B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Jul 29, 2025
AZN.NB Final Cash Dividend of gross USD 0.515 paid on Sep 08, 2025 going ex on Aug 08, 2025
Aug 08, 2025
Sep 08, 2025
Aug 08, 2025
Feb 06, 2025
AZN.NB Interim Cash Dividend of gross USD 1.05 paid on Mar 24, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Mar 24, 2025
Feb 21, 2025
Jul 25, 2024
AZN.NB Final Cash Dividend of gross USD 0.5 paid on Sep 09, 2024 going ex on Aug 09, 2024
Aug 09, 2024
Sep 09, 2024
Aug 09, 2024
Feb 08, 2024
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 25, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Mar 25, 2024
Feb 22, 2024
Jul 28, 2023
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 11, 2023 going ex on Aug 10, 2023
Aug 11, 2023
Sep 11, 2023
Aug 10, 2023
Feb 10, 2023
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 27, 2023 going ex on Feb 23, 2023
Feb 24, 2023
Mar 27, 2023
Feb 23, 2023
Aug 01, 2022
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 12, 2022 going ex on Aug 11, 2022
Aug 12, 2022
Sep 12, 2022
Aug 11, 2022
Feb 10, 2022
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 28, 2022 going ex on Feb 24, 2022
Feb 25, 2022
Mar 28, 2022
Feb 24, 2022
Aug 02, 2021
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 13, 2021 going ex on Aug 12, 2021
Aug 13, 2021
Sep 13, 2021
Aug 12, 2021
Feb 11, 2021
AZN.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2021 going ex on Feb 25, 2021
Feb 26, 2021
Mar 29, 2021
Feb 25, 2021
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
阿斯利康的前五大股东是谁？
阿斯利康 的前五大股东如下：
PRIMECAP Management Company持有股份：41.20M，占总股份比例：1.33%。
Wellington Management Company, LLP持有股份：34.34M，占总股份比例：1.11%。
T. Rowe Price International Ltd持有股份：30.71M，占总股份比例：0.99%。
Capital International Investors持有股份：31.40M，占总股份比例：1.01%。
Managed Account Advisors LLC持有股份：21.15M，占总股份比例：0.68%。
PRIMECAP Management Company持有股份：41.20M，占总股份比例：1.33%。
Wellington Management Company, LLP持有股份：34.34M，占总股份比例：1.11%。
T. Rowe Price International Ltd持有股份：30.71M，占总股份比例：0.99%。
Capital International Investors持有股份：31.40M，占总股份比例：1.01%。
Managed Account Advisors LLC持有股份：21.15M，占总股份比例：0.68%。
阿斯利康的前三大股东类型是什么？
阿斯利康 的前三大股东类型分别是：
PRIMECAP Management Company
Wellington Management Company, LLP
T. Rowe Price International Ltd
PRIMECAP Management Company
Wellington Management Company, LLP
T. Rowe Price International Ltd
有多少机构持有阿斯利康(AZN)的股份？
截至2025Q4，共有2038家机构持有阿斯利康的股份，合计持有的股份价值约为518.15M，占公司总股份的17.29%。与2025Q3相比，机构持股有所增加，增幅为-0.05%。
哪个业务部门对阿斯利康的收入贡献最大？
在FY2025Q2，Farxiga业务部门对阿斯利康的收入贡献最大，创收2.15B，占总收入的15.59%。
